Allogene Therapeutics (ALLO)
(Real Time Quote from BATS)
$2.48 USD
+0.02 (0.81%)
Updated May 31, 2024 11:32 AM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Allogene Therapeutics, Inc. [ALLO]
Reports for Purchase
Showing records 181 - 200 ( 213 total )
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare-Check Out Our Highlights From 2020 ASCO Abstracts
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Register for Our Webinar: ACSO Abstract Titles Review '-' April 30th at 10am ET
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Market Shudders But We See Names to Outperform.
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 Causes ALL Trial Disruption. ALLO-501 Data in 2Q20.
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Consider Reading Vol. 7: Observations From Treatment Responsive Cancer Patients
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Allo CAR T''s, Transitioning From the Aspirational to the Achievable
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
"Consider Reading" Vol. 1: Could c-Jun Enhance CAR-T Therapeutics?
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - Key Takeaways From Our KOL Event Series at ASH 2019
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T